Aug 20, 2026 05:00PM
May 14, 2026 06:00PM
Mar 19, 2026 05:30PM
Mar 2, 2026 08:30AM
Feb 9, 2026 07:30AM
Feb 9, 2026 07:30AM
Dec 15, 2025 04:30PM BioSyent Announces Renewal of Normal Course Issuer Bid
Nov 20, 2025 05:30PM
Aug 21, 2025 04:45PM
May 15, 2025 05:45PM
Mar 13, 2025 05:30PM
Jan 6, 2025 05:18PM
Dec 16, 2024 08:30AM
Nov 25, 2024 05:53PM FAX Capital Files Early Warning Report Regarding Disposition of Common Shares of BioSyent Inc.
Nov 20, 2024 08:00AM
Sep 20, 2024 09:00AM
Jul 24, 2024 07:36PM
Dec 13, 2023 08:00AM
Dec 13, 2022 08:00AM
Mar 29, 2022 05:37PM
Dec 13, 2021 08:00AM BioSyent Announces Renewal of Normal Course Issuer Bid
Jun 11, 2021 07:30AM
May 5, 2021 08:42AM
Dec 11, 2020 08:00AM
Dec 11, 2019 08:00AM
Dec 4, 2018 08:00AM
Aug 19, 2015 08:00AM
Aug 12, 2015 08:00AM BioSyent Releases First Six Months 2015 Results-Six Month Sales Up 25%; Pharma Sales Up 25%; EBITDA Up 31%; Net Income Up 30%; Return on Equity 40%
May 13, 2015 04:21PM
May 13, 2015 08:00AM
May 1, 2015 04:01PM
Apr 10, 2015 08:00AM

1,182,407 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All